New Malaria Vaccine may be too Costly for Success

by Bidita Debnath on  October 23, 2013 at 10:52 PM Research News   - G J E 4
A promising new malaria vaccine being tested by GlaxoSmithKline is a step in the right direction, but much more economical methods are needed.
 New Malaria Vaccine may be too Costly for Success
New Malaria Vaccine may be too Costly for Success

Laura Harrington, professor of entomology at Cornell University and an expert in global health and epidemiology, said that despite a resurgence in the global effort to fight malaria, the war on this deadly mosquito borne infection has overwhelmed scientists, policy makers, and government officials alike.

She said that major challenges, like behavioral and biochemical resistance by malaria vectors, and the flood of fake antimalarial drugs in the marketplace have all taken their toll.

Harrington asserted that the world's first successful malaria vaccine is almost within reach. A malaria vaccine has long been viewed as the 'holy grail of tropical medicine.'

Although the GlaxoSmithKline RTS vaccine doesn't protect all immunized children - only a 46 percent reduction in malaria incidence for children 5 to 17 months, and 27 percent for those 6 to 12 weeks of age - it is better than no vaccine, and it could be used together with other strategies like vector control to reduce malaria illness and mortality.

Source: ANI

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like